This study of a new cream for the treatment of mild to moderate facial angiofibromas is underway in the United States and across the globe. It is anticipated that approximately 120 patients, aged 6-65, will participate in this trial over the next several months.
Participation in the study will last roughly 8 months, including screening and follow up periods. If you qualify for the study, you will be responsible for daily application of the cream and completing a diary.
For additional information on this study, including contact information on all participating study sites and detailed eligibility criteria, please visit clinicaltrials.gov and enter NCT number NCT03826628.
If you or a family member are interested in this study, or have any questions you may also contact us at trials@timberpharma.com.
